Bristol-Myers Squibb (BMY) said Monday that its phase 3 Odyssey-HCM trial, which evaluated Camzyos in adults with symptomatic New York Heart Association class II-III non-obstructive hypertrophic cardiomyopathy, did not meet its dual primary endpoints.

The trial failed to show a statistically significant difference from placebo in changes from baseline to week 48 in both the Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score and peak oxygen consumption.

No new safety signals were observed, the company added.

Shares of Bristol-Myers Squibb were down 2% in after-hours trading.